Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market size and forecast PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE LANDSCAPE PART 09: MARKET SEGMENTATION BY THERAPEUTIC APPLICATION • Comparison by therapeutic application • Gastrointestinal disorders • Immunological conditions • Others • Market opportunity by therapeutic application PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Comparison by region • Human microbiome therapeutics market in Americas • Human microbiome therapeutics market in EMEA • Human microbiome therapeutics market in APAC • Key leading countries • Market opportunity by region PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Increase in industry-academia collaboration • Increasing investments by venture capitalists PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive analysis PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ENTEROME Bioscience • Rebiotix • Seres Therapeutics • Vedanta Biosciences PART 17: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Microbiome by host Exhibit 02: Common prebiotics Exhibit 03: Major sources of prebiotics Exhibit 04: Benefits of probiotics Exhibit 05: Parent market Exhibit 06: Global human microbiome therapeutics market: Characteristics Exhibit 07: Global human microbiome therapeutics market: Segmentation Exhibit 08: Market definition: Inclusions and exclusions checklist Exhibit 09: Market size 2017 Exhibit 10: Validation techniques employed for market sizing 2017 Exhibit 11: Global human microbiome therapeutics market 2017-2022 ($ millions) Exhibit 12: Global human microbiome therapeutics market: Year-over-year growth Exhibit 13: Five forces analysis 2017 Exhibit 14: Five forces analysis 2022 Exhibit 15: Bargaining power of buyers Exhibit 16: Bargaining power of suppliers Exhibit 17: Threat of new entrants Exhibit 18: Threat of substitutes Exhibit 19: Threat of rivalry Exhibit 20: Market condition: Five forces 2017 Exhibit 21: Pipeline landscape Exhibit 22: Key clinical trials Exhibit 23: Global human microbiome therapeutics market by therapeutic application 2017-2022 (% share) Exhibit 24: Comparison by therapeutic application Exhibit 25: Global human microbiome therapeutics market by gastrointestinal disorders 2017-2022 ($ millions) Exhibit 26: Global human microbiome therapeutics market by gastrointestinal disorders: Year-over-year growth 2018-2022 Exhibit 27: Global human microbiome therapeutics market by immunological conditions 2017-2022 ($ millions) Exhibit 28: Global human microbiome therapeutics market by immunological conditions: Year-over-year growth 2018-2022 Exhibit 29: Global human microbiome therapeutics market by others 2017-2022 ($ millions) Exhibit 30: Global human microbiome therapeutics market by others: Year-over-year growth 2018-2022 Exhibit 31: Market opportunity by therapeutic application Exhibit 32: Customer landscape Exhibit 33: Global human microbiome therapeutics market by region 2017-2022 (% share) Exhibit 34: Regional comparison Exhibit 35: Human microbiome therapeutics market in Americas 2017-2022 ($ millions) Exhibit 36: Human microbiome therapeutics market in Americas: Year-over-year growth Exhibit 37: Human microbiome therapeutics market in EMEA 2017-2022 ($ millions) Exhibit 38: Human microbiome therapeutics market in EMEA: Year-over-year growth 2018-2022 Exhibit 39: Human microbiome therapeutics market in APAC 2017-2022 ($ millions) Exhibit 40: Human microbiome therapeutics market in APAC: Year-over-year growth 2018-2022 Exhibit 41: Top Asian countries in terms of population with diabetes (millions) Exhibit 42: Key leading countries Exhibit 43: Market opportunity by region Exhibit 44: Global obesity facts 2014 Exhibit 45: Factors causing changes in human microbiome Exhibit 46: Antibiotic resistance steps Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Competitive structure analysis of global microbiome therapeutics market Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: ENTEROME Bioscience: Overview Exhibit 54: ENTEROME Bioscience: Business segments Exhibit 55: ENTEROME Bioscience: Organizational developments Exhibit 56: ENTEROME Bioscience: Geographic focus Exhibit 57: ENTEROME Bioscience: Segment focus Exhibit 58: ENTEROME Bioscience: Key offerings Exhibit 59: Rebiotix: Overview Exhibit 60: Rebiotix: Business segments Exhibit 61: Rebiotix: Organizational developments Exhibit 62: Rebiotix: Geographic focus Exhibit 63: Rebiotix: Segment focus Exhibit 64: Rebiotix: Key offerings Exhibit 65: Seres Therapeutics: Overview Exhibit 66: Seres Therapeutics: Business segments Exhibit 67: Seres Therapeutics: Organizational developments Exhibit 68: Seres Therapeutics: Geographic focus Exhibit 69: Seres Therapeutics: Segment focus Exhibit 70: Seres Therapeutics: Key offerings Exhibit 71: Vedanta Biosciences: Overview Exhibit 72: Vedanta Biosciences: Business segments Exhibit 73: Vedanta Biosciences: Organizational developments Exhibit 74: Vedanta Biosciences: Geographic focus Exhibit 75: Vedanta Biosciences: Segment focus Exhibit 76: Vedanta Biosciences: Key offerings

ENTEROME Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.